Holen Sie sich die Stockscreener-App
2.51
4.20%
-0.11
Handel nachbörslich:
2.50
-0.010
-0.40%
Schlusskurs vom Vortag:
$2.62
Offen:
$2.58
24-Stunden-Volumen:
7.40M
Relative Volume:
1.82
Marktkapitalisierung:
$270.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-258.08M
KGV:
-0.9127
EPS:
-2.75
Netto-Cashflow:
$-202.32M
1W Leistung:
-59.97%
1M Leistung:
-65.52%
6M Leistung:
-82.56%
1J Leistung:
-88.30%
1-Tages-Spanne:
$2.40
$2.61
1-Wochen-Bereich:
$2.19
$2.785
52-Wochen-Spanne:
$2.19
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Vergleichen Sie RCKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
2.51 | 675.52M | 0 | -258.08M | -202.32M | -2.75 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Needham | Buy → Hold |
| 2025-05-27 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-30 | Eingeleitet | Wedbush | Outperform |
| 2024-12-18 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-11-01 | Eingeleitet | BTIG Research | Buy |
| 2022-07-08 | Eingeleitet | Raymond James | Outperform |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2021-02-18 | Eingeleitet | Needham | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
| 2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to In-Line Rating by Evercore ISI - Defense World
Wedbush Brokers Increase Earnings Estimates for RCKT - Defense World
Leerink Partnrs Issues Optimistic Forecast for RCKT Earnings - Defense World
Securities Investigation: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) on Behalf of Investors - ACCESS Newswire
RCKT ACTIVE INVESTIGATION: Lost Money on Rocket Pharmaceuticals, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setba - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setback | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Downgrade with New Price Target | RCKT Stock News - GuruFocus
Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target - marketscreener.com
Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) to In Line, 'removing from the SMID Core List' - StreetInsider
Jane Street Group LLC Has $508,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Millennium Management LLC Sells 865,586 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
RCKT ALERT: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
Ongoing Investigation: Rocket Pharmaceuticals, Inc. (RCKT) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies - MSN
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback - MSN
JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44 - marketscreener.com
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. - AOL.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow - Insider Monkey
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty - Benzinga
Rocket Pharmaceuticals (RCKT) Faces Downgrade After Clinical Hol - GuruFocus
Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact - Seeking Alpha
Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death - MSN
Rocket Pharmaceuticals (RCKT) Analyst Rating Update: May 2025 | - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Scotiabank | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Sees Significant Analyst Downgrade - GuruFocus
Rocket Pharmaceuticals (RCKT) Sees Significant Analyst Downgrade | RCKT Stock News - GuruFocus
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Deutsche Bank AG - Defense World
RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance
Rocket Pharmaceuticals (RCKT) Faces Price Target Cut Amid Clinical Hold | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Receives Downgrade and Price Targe - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Downgrade Amid Clinical Tria - GuruFocus
Rocket Pharmaceuticals (RCKT) Target Price Revised by Chardan Ca - GuruFocus
Rocket Pharmaceuticals (RCKT) Target Price Revised by Chardan Capital | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Challenges After Clinical Hold | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Price Target Cut Amidst Clin - GuruFocus
Scotiabank cuts Rocket Pharmaceuticals target to $19 - Investing.com
Chardan Cuts Price Target on Rocket Pharmaceuticals to $17 From $46, Keeps Buy Rating - marketscreener.com
This Informatica Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Jefferies Downgrades Rocket Pharmaceuticals (RCKT) Rating and Pr - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Setback Amid Clinical Trial Death | RCKT Stock News - GuruFocus
Needham Downgrades Rocket Pharmaceuticals to Hold From Buy - marketscreener.com
Rocket Pharmaceuticals (RCKT) Downgraded by Jefferies Amid FDA H - GuruFocus
Rocket Pharmaceuticals (RCKT) Downgraded by Jefferies Amid FDA Hold | RCKT Stock News - GuruFocus
Morgan Stanley cuts Rocket Pharmaceuticals stock rating, slashes PT - Investing.com
Jefferies cuts Rocket Pharmaceuticals stock rating, slashes target - Investing.com
Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery - Investing.com India
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):